Category Archives: C. MIND-BODY THERAPIES

Is CAM cost effective treatment?

Three criteria determine drug reimbursement decisions: therapeutic value, cost effectiveness, and burden of disease. Now, an article from Erasmus University in The Netherlands questions whether it’s sufficient for a drug to meet these criteria, and proposes a 4th hurdle.

Consider how CAM would hold up under such scrutiny based on what we know today. Continue reading Is CAM cost effective treatment? →

Limits of long-term narcotic use to treat back pain and CAM options

Narcotic drugs (opioids) are commonly prescribed for short-term relief of chronic back pain, but their long-term (greater than 16 weeks) effectiveness has never been proved.

Also, opioid abuse occurs in 24% of cases.

What’s this got to do with CAM?

Continue reading Limits of long-term narcotic use to treat back pain and CAM options →

Use of CAM among children with ADHD

About 9% of US children age 8 to 15 meet the diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD), but fewer than half receive treatment, according to a report in the September issue of Archives of Pediatrics & Adolescent Medicine.

According to an earlier survey of more than 800 parents of children with ADHD. About 12% of children with diagnosed ADHD and 7% of those suspected of having ADHA use CAM.
What do they use?

Continue reading Use of CAM among children with ADHD →

A new tool to test the biological effects of biofeedback, meditation, and yoga

OK. Stay with me on this.

Kevin Tracey, MD is director and CEO of The Feinstein Institute for Medical Research in New York. A well-respected researcher, Dr. Tracey discovered that the brain controls the immune system via the vagus nerve. Now he’s investigating the role of a molecule called tumor necrosis factor (TNF) as part of the immune system’s weapons against foreign invaders. TNF can cause pain and redness to an injury or infection. In excessive amounts, it can also cause shock and death.

What’s this got to do with CAM?

Maybe a lot.

Continue reading A new tool to test the biological effects of biofeedback, meditation, and yoga →

Should cognitive behavioral therapy be added to antidepressant therapy?

A study in the British Medical Journal concludes that adding weekly cognitive behavioral therapy (CBT) to treatment with the selective serotonin reuptake inhibitor (SSRI) fluoxetine (Prozac) was no more beneficial for depressed adolescents than medication alone.

A closer look suggests the Adolescent Depression Antidepressant and Psychotherapy Trial (ADAPT) is not the definitive study on this subject.

Here’s why. Continue reading Should cognitive behavioral therapy be added to antidepressant therapy? →

Experts respond to the negative AHRQ report on meditation

The report by the University of Alberta Evidence-based Practice Center (UAEPC) after reviewing the published literature on meditation practices for health were published here and discussed here.

The authors found so many flaws in the design of the studies that “conclusions on the effects of meditation practices in healthcare cannot be drawn based on the available evidence.” The report was funded by the NIH Agency for Healthcare Research and Quality (AHRQ). Continue reading Experts respond to the negative AHRQ report on meditation →

Dissapointing recommendations to treat Alzheimer’s disease

These recommendations, from a group of experts, take a narrow view of Alzheimer’s disease. They focus on early detection and the use of existing prescription drugs.

That’s fine as far as it goes, but what about those with advanced Alzheimer’s? Why not develop a more comprehensive approach?

If I might quote Paul Harvey, “here’s the rest of the story.” Continue reading Dissapointing recommendations to treat Alzheimer’s disease →